A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
This research study is looking into a new medication called Aritinercept for people who have Generalized Myasthenia Gravis, a condition that causes muscle weakness. It's a 'double-blind' study, meaning neither you nor your doctor will know if you're getting the new medicine or a dummy treatment (placebo). This helps us get clearer results. The main goals are to check if the new medicine is safe and to see if it helps improve daily tasks for people with Myasthenia Gravis. We also want to understand how the body handles the medicine and if it causes any unwanted reactions. This is an early stage of testing, combining two phases to learn more quickly.
At a glance
What is this study about?
This study is about understanding a new medicine called Aritinercept for people living with Generalized Myasthenia Gravis. Myasthenia Gravis is a condition that makes your muscles weak and tired, which can make everyday activities challenging. The new medicine, Aritinercept, is designed to target specific proteins in the body that are thought to play a role in this condition.
In this study, researchers want to find out two main things. Firstly, they want to make sure the medicine is safe and to track any side effects people might experience. Secondly, they want to see if the medicine actually helps people. They'll measure this by looking at how well people can do their normal daily activities, like eating, dressing, or walking, after taking the medicine.
Because this is a 'double-blind' study, some participants will receive the new medicine and others will receive a 'placebo', which looks identical but contains no active medicine. Neither you nor your study doctor will know which you are receiving until the study is over. This helps ensure the results are fair and accurate. It's an important step in developing new treatments for Myasthenia Gravis.
Key takeaways
- This study is testing a new medicine for Myasthenia Gravis.
- It aims to find out if the medicine is safe and if it helps with daily activities.
- It's a 'double-blind' study, meaning some will get the medicine, some a placebo.
- Participation involves regular clinic visits and health checks.
- You must be 18 years or older to be considered.
- You can withdraw from the study at any time.
Who may be eligible?
To be considered for this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
More detailed specific requirements, such as your current health status, other medications you might be taking, and your history with Myasthenia Gravis, will be discussed by the study team. These details are important to make sure the study is safe and appropriate for you.
It's important to remember that meeting the basic age and gender requirements doesn't guarantee you'll be able to join. The study doctors will carefully review your health information to make sure the study is suitable for you and that taking part won't put your health at risk.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of Generalized Myasthenia Gravis?
- Are you able to attend regular clinic appointments?
- Are you willing to potentially receive a placebo?
- Are you comfortable with blood tests and health assessments?
What does participation involve?
If you decide to participate, you would be randomly assigned to receive either the new medicine (Aritinercept) or a placebo (a dummy treatment). You would receive regular doses, likely given as an injection, over a period of time, which the study team will explain in detail. There will be several visits to the clinic for assessments.
During these visits, the study team will monitor your health, ask you questions about how you are feeling, and perform various tests. These tests might include blood samples to check how your body is reacting to the medicine and how much of it is in your system. They will also assess your muscle strength and your ability to carry out daily activities using specific questionnaires.
The total duration of your participation, including the treatment period and any follow-up appointments, will be clearly explained by the study team. This type of study often involves regular check-ups over several months.
Potential risks and benefits
Locations (1)
- —UnverifiedPoland
Common questions
What is Myasthenia Gravis?
It's a condition that causes muscle weakness and tiredness, affecting how your muscles and nerves communicate.
What is a 'double-blind' study?
It means neither you nor your doctor will know if you're receiving the new medicine or a placebo, to keep the results fair.
What is a placebo?
A placebo looks like the real medicine but doesn't contain any active drug. It helps compare the new medicine's effects.
Will I have to pay to be in the study?
No, you will not have to pay for the study treatment or for taking part in the research visits.
Can I stop participating if I want to?
Yes, you can choose to leave the study at any time, for any reason, without it affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.